crimeancongo
haemorrhag
fever
cchf
viru
broad
global
distribut
tick
belong
genu
hyalomma
infect
cchf
viru
whose
lineag
match
viru
strain
mauritania
seneg
identifi
extremadura
diagnos
august
spain
human
case
autochthon
acquisit
report
western
europ
cchf
viru
belong
famili
bunyavirida
genu
nairoviru
main
vector
tick
belong
genu
hyalomma
differ
anim
domest
wild
act
reservoir
viru
cat
sheep
goat
hors
donkey
pig
hare
hedgehog
etc
livestock
one
import
host
human
be
may
infect
either
tick
bite
direct
handl
infect
meat
fluid
nosocomi
transmiss
report
healthcar
staff
accident
needl
stick
unprotect
exposur
blood
bodili
fluid
droplet
patient
diagnos
cchf
infect
also
report
healthcar
worker
involv
care
ill
patient
without
exact
rout
transmiss
identifi
articl
case
infect
clear
sourc
account
nosocomi
case
spectrum
serious
cchf
highli
variabl
seropreval
studi
endem
area
suggest
case
asymptomat
classic
clinic
cours
cchf
divid
four
period
incub
prehaemorrhag
phase
haemorrhag
phase
convalesc
report
mortal
rang
depend
outbreak
studi
mortal
primarili
caus
fulmin
hepat
thrombocytopenia
massiv
bleed
turkey
sinc
first
case
identifi
case
report
mortal
rate
approxim
remain
stabl
year
cchf
viru
classifi
biosafeti
level
pathogen
capabl
interperson
transmiss
advis
manag
patient
suspect
confirm
diagnosi
cchf
use
strict
precaut
contact
patient
isol
individu
room
prefer
separ
entranc
exit
virus
isol
biosafeti
level
highcontain
laboratori
patient
cchf
manag
highlevel
isol
unit
support
therapi
essenti
sinc
effect
specif
aetiolog
treatment
although
use
controversi
conclus
studi
demonstr
efficaci
seriou
case
advis
use
highdos
ribavirin
treatment
hyperimmun
serum
convalesc
patient
shown
use
furthermor
vaccin
proven
efficaci
safeti
human
cchf
viru
biosafeti
level
pathogen
transmiss
capabl
caus
nosocomi
outbreak
high
mortal
rate
contact
contamin
materi
fluid
contact
blood
gastrointestin
bleed
accident
needl
stick
surgic
oper
patient
unknown
diagnosi
report
main
rout
infect
healthcar
set
close
interperson
contact
patient
manipul
respiratori
tract
rout
transmiss
still
subject
debat
howev
nosocomi
outbreak
cchf
inde
report
orotrach
intub
viru
limit
repercuss
domest
set
show
invas
procedur
unprotect
contact
haemorrhag
phase
caus
secondari
case
ideal
patient
cchf
receiv
care
highlevel
isol
unit
equip
critic
care
cchf
may
progress
rapid
deterior
room
equip
neg
pressur
system
procedur
gener
droplet
need
perform
healthcar
staff
well
inform
diseas
possibl
mechan
infect
also
suitabl
educ
regular
train
put
take
person
protect
equip
ppe
emerg
depart
endem
region
receiv
instruct
uphold
strict
contact
precaut
ensur
isol
suspect
case
start
retrospect
studi
found
around
case
nosocomi
infect
origin
patient
yet
diagnos
cchf
although
univers
basic
protect
barrier
could
suffic
prevent
case
nosocomi
infect
note
hospit
care
provid
serious
ill
patient
greater
viraemia
exist
evid
nosocomi
outbreak
world
health
organis
recommend
highli
lethal
haemorrhag
fever
justifi
use
ppe
compris
least
follow
item
waterproof
gown
glove
mask
goggl
face
screen
clinic
manag
confirm
case
advis
use
ppe
use
manag
ebola
viru
diseas
waterproof
bodi
suit
doubl
layer
footwear
glove
hood
mask
airtight
goggl
ppe
must
alway
suit
type
healthcar
provid
risk
infect
may
vari
therapeut
manag
drug
administ
via
intramuscular
inject
prevent
haematoma
local
bleed
punctur
site
advis
administ
paracetamol
antipyret
avoid
nonsteroid
antiinflammatori
drug
extent
possibl
due
potenti
repercuss
clot
proton
pump
inhibitor
may
use
prevent
gastrointestin
bleed
may
occur
due
either
diseas
complic
stress
women
inhibit
menstrual
bleed
administr
progesteron
may
indic
although
antimicrobi
use
confirm
case
cchf
unless
superinfect
suspect
must
consid
investig
case
assess
differ
entiti
includ
differenti
diagnosi
patient
geograph
origin
differenti
diagnosi
cchf
broad
patient
geograph
origin
taken
account
includ
alkhurma
haemorrhag
fever
rift
valley
fever
middl
east
omsk
haemorrhag
fever
russia
kyasanur
forest
diseas
india
hantaviru
europ
asia
lassa
viru
ebola
viru
marburg
viru
rift
valley
fever
yellow
fever
africa
dengu
fever
mainli
asia
central
africa
tropic
subtrop
countri
malaria
import
altern
diagnosi
rule
transmiss
vector
taken
account
follow
must
also
includ
rickettsia
spp
ehrlichia
spp
borrelia
anaplasma
babesia
addit
mani
infecti
diseas
may
featur
similar
initi
clinic
pictur
tularaemia
q
fever
coxiella
burnetii
viral
hepat
influenza
viru
infect
meningococc
mening
leptospirosi
typhoid
fever
sepsi
due
staphylococci
gramneg
bacilli
toxic
shock
syndrom
salmonellosi
shigellosi
psittacosi
trypanosomiasi
septic
infect
due
yersinia
pesti
rubella
measl
efficaci
glucocorticoid
treatment
cchf
confirm
studi
dedic
evalu
use
limit
consist
small
case
seri
adult
paediatr
patient
found
administr
highdos
methylprednisolon
mgday
seem
promot
earli
haematolog
recoveri
revers
haemorrhag
lesion
decreas
need
transfus
blood
product
result
inconclus
due
patient
simultan
receiv
ribavirin
patient
develop
haemophiliac
syndrom
secondari
cchf
treatment
corticosteroid
would
clearli
indic
sinc
demonstr
efficaci
case
secondari
infect
microorgan
support
therapi
care
patient
cchf
requir
care
monitor
vital
sign
detect
organ
failur
earli
start
necessari
support
care
immedi
cchf
requir
close
laboratori
monitor
complet
blood
count
alanin
nontransfer
alt
aspartam
nontransfer
tabl
situat
platelet
transfus
recommend
acut
massiv
bleed
hypovolaem
shock
patient
platelet
count
mm
bleed
diathesi
patient
platelet
count
mm
requir
emerg
surgeri
invas
procedur
patient
platelet
count
mm
fever
clot
abnorm
patient
platelet
count
mm
ast
total
rubin
creat
intern
normalis
ratio
inr
activ
partial
thromboplastin
time
aptt
creatin
kinas
lactat
dehydrogenas
case
platelet
count
mm
would
advis
perform
least
two
round
laboratori
test
per
day
dissemin
intravascular
coagul
dic
suspect
ddimer
arteri
blood
ga
valu
obtain
suitabl
electrolyt
replac
must
ensur
fluid
therapi
must
adjust
hypoton
solut
avoid
event
kidney
failur
would
requir
renal
replac
therapi
haemodialysi
prefer
periton
dialysi
patient
may
develop
levelofconsci
abnorm
seizur
coma
respiratori
failur
necessit
endotrach
intub
done
extrem
care
prevent
bleed
healthcar
team
strictli
protect
seriou
case
haemorrhag
sign
occur
day
onset
fever
treatment
platelet
concentr
tabl
platelet
concentr
obtain
apheresi
singl
donor
recommend
involv
separ
select
blood
compon
donor
decreas
immunogen
potenti
compar
transfus
multipl
donor
volum
transfus
unit
per
kg
bodi
weight
differ
lie
fact
obtain
equival
platelet
unit
case
multipl
donor
differ
transfus
requir
versu
one
plateletpheresi
transfus
indic
due
activ
bleed
shall
perform
demand
base
clinic
respons
laboratori
test
perform
h
follow
administr
increas
around
plateletsl
possibl
alloimmunis
event
due
antihla
antibodi
dic
complic
sepsi
must
consid
fresh
plasma
may
use
case
massiv
haemorrhag
liver
failur
thrombocytopen
thrombot
purpura
dilut
coagulopathi
dic
vitamin
k
defici
inr
time
normal
limit
decreas
aptt
offer
advantag
higher
concentr
clot
factor
compar
blood
product
dose
administ
mlkg
dose
depend
laboratori
respons
monitor
use
caution
heart
failur
present
commerci
prepar
deriv
human
plasma
protein
avail
use
clot
disord
undergo
cell
filtrat
treat
solventsdeterg
neutralis
antileukocyt
antibodi
reduc
bioactiv
lipid
elimin
viral
agent
role
context
cchf
studi
might
use
refractori
thrombocytopenia
thank
immunomodul
activ
howev
data
use
cchf
anecdot
antivir
drug
proven
efficaci
cchf
viru
one
main
problem
research
activ
drug
viru
lack
anim
model
cchf
viru
pathogen
anim
except
human
be
diseas
report
mammal
intact
immun
system
date
model
avail
infant
immunodefici
mous
model
ribavirin
ribavirin
antivir
drug
extens
experi
use
cchf
controversi
data
synthet
antivir
guanosin
analogu
show
broad
antivir
spectrum
includ
dna
rna
virus
wide
use
combin
interferon
treatment
hepat
c
viru
infect
although
demonstr
antivir
activ
cchf
viru
studi
vitro
infant
mous
model
data
efficaci
human
base
observ
studi
singl
openlabel
clinic
trial
two
metaanalys
ribavirin
would
indic
earli
prehaemorrhag
phase
sinc
viraemia
greatest
haemorrhag
phase
begin
viraemia
usual
decreas
pathogen
factor
coagulopathi
dissemin
intravascular
coagul
cytokin
storm
predomin
pathophysiolog
order
evalu
efficaci
data
use
ribavirin
critic
know
point
cours
cchf
drug
administr
startedin
koksal
et
al
conduct
randomis
clinic
trial
hospit
centr
turkey
compar
ad
versu
ad
ribavirin
support
therapi
versu
patient
respect
found
differ
group
term
either
surviv
length
stay
two
metaanalys
perform
also
find
use
ribavirin
benefit
note
studi
includ
metaanalysi
nonrandomis
nonblind
prospect
studi
except
abovement
clinic
trial
furthermor
limit
number
overal
mortal
rate
patient
receiv
ribavirin
contrast
mortal
rate
patient
receiv
ribavirin
recommend
use
ribavirin
cchf
although
recommend
support
lassa
fever
ultim
evid
efficaci
ribavirin
treatment
cchf
must
improv
conduct
clinic
trial
although
conduct
placebocontrol
clinic
trial
may
pose
ethic
problem
present
nonplacebocontrol
clinic
trial
conduct
intraven
ribavirin
one
cchf
lassa
fever
led
us
armi
medic
research
materi
command
current
consensu
among
expert
use
ribavirin
seriou
case
prefer
intraven
prevent
hepat
first
pass
effect
achiev
plasma
level
quickli
recommend
dose
ribavirin
vari
sourc
consult
regimen
day
initi
load
dose
mgkg
follow
mgkg
everi
h
day
mgkg
everi
h
day
recommend
oral
administr
recommend
administ
initi
load
dose
g
follow
dose
g
everi
h
day
finish
regimen
fifth
sixth
day
treatment
mg
everi
h
side
effect
known
experi
treatment
hcv
infectionhaemolyt
anaemia
aplast
anaemia
kidney
failur
hypocalcaemia
hypomagnesaemia
acut
cholestat
hepat
might
appear
often
dose
administ
four
time
greater
ribavirin
contraind
pregnant
women
favipiravir
nucleosid
analogu
activ
rna
virus
present
approv
japan
treatment
influenza
viru
infect
activ
vitro
bunyaviru
arenaviru
filoviru
demonstr
activ
cchf
viru
mous
model
case
cchf
viru
studi
conduct
mice
compar
efficaci
ribavirin
umifenovir
favipiravir
anim
treat
favipiravir
first
hour
least
two
day
surviv
ribavirin
prolong
time
death
increas
surviv
rate
umifenovir
yield
benefit
ultim
favipiravir
could
treatment
cchf
data
use
human
record
clinic
trial
progress
chloroquin
chlorpromazin
demonstr
certain
antivir
effect
chloroquin
shown
activ
rna
virus
intracellular
bacteria
chlorpromazin
demonstr
activ
adenoviru
ebola
viru
coronaviru
inhibit
viral
endocytosi
serum
convalesc
patient
publish
case
infect
cchf
viru
treat
intramuscularli
intraven
hyperimmun
serum
convalesc
patient
result
encourag
especi
group
patient
high
viral
load
surviv
rate
around
ill
patient
lack
clinic
trial
control
group
observ
studi
obstacl
recommend
routin
use
monoclon
antibodi
studi
conduct
mous
model
one
subgroup
achiev
protect
follow
administr
antibodi
nonneutralis
antibodi
seen
protect
anim
death
suggest
antibodymedi
respons
depend
also
host
factor
gener
factor
associ
poor
prognosi
includ
follow
age
year
underli
comorbid
rapid
deterior
clinic
condit
acceler
worsen
laboratori
valu
tabl
swanepoel
et
al
report
mortal
rate
presenc
follow
laboratori
abnorm
first
five
day
leukocyt
l
platelet
l
ast
ul
alt
ul
aptt
fibrinogen
mgdl
bakir
et
al
propos
prognost
score
subsequ
valid
extern
cohort
tabl
score
take
valu
time
admiss
patient
score
less
equal
surviv
score
mortal
rate
score
greater
equal
mortal
rate
sourc
akinzi
et
al
final
viral
load
also
close
link
prognosi
level
excess
copiesml
associ
high
mortal
inform
publish
discharg
criteria
divers
sometim
controversi
part
endem
region
cchf
healthcar
system
similar
western
europ
gener
recommend
haemorrhag
fever
consid
safe
discharg
patient
isol
patient
experi
clinic
improv
disappear
symptom
enabl
autonomi
basic
vital
function
least
one
neg
blood
pcr
less
h
last
posit
pcr
howev
turkey
discharg
recommend
base
clinic
data
absenc
symptom
least
three
day
laboratori
data
platelet
mm
normalis
clot
descend
curv
transaminas
need
neg
pcr
cchf
viru
turkish
centr
even
limit
confirm
absenc
fever
h
disappear
complic
particular
diseas
clinic
laboratori
discharg
criteria
seem
safe
patient
prevent
commun
transmiss
diseas
accord
data
prospect
multicentr
analysi
conduct
turkey
ribavirin
use
ribavirin
postexposur
prophylaxi
controversi
recommend
limit
highestrisk
case
direct
contact
fluid
contamin
mucosa
conjunctiva
fluid
accident
needl
stick
clear
consensu
term
dose
therapeut
regimen
start
load
dose
g
per
day
follow
g
per
day
four
day
end
g
per
day
six
day
etc
administr
indic
start
earli
vaccin
clinic
trial
identifi
vaccin
proven
efficaci
clinic
trial
difficult
conduct
outbreak
sporad
irregular
number
case
earli
trial
russia
vaccin
deriv
mous
brain
tissu
inactiv
formaldehyd
show
limit
antibodi
respons
increas
revaccin
year
demonstr
increas
antibodi
week
third
dose
decreas
antibodi
month
later
data
vaccin
subsequ
publish
two
experiment
vaccin
first
obtain
infect
mous
brain
cell
inactiv
chloroform
trial
conduct
bulgaria
fewer
particip
found
seroconvers
rate
around
anoth
studi
popul
vaccin
everi
two
year
detect
signific
antibodi
receiv
biannual
booster
suggest
regimen
consist
first
dose
second
dose
day
later
booster
one
year
follow
revaccin
everi
five
year
bulgarian
ministri
health
report
number
case
report
due
cchf
decreas
factor
four
howev
subsequ
studi
fulli
support
use
second
experiment
vaccin
dna
vaccin
base
segment
viru
vaccin
shown
develop
neutralis
antibodi
mice
subsequ
market
none
abovement
vaccin
approv
use
european
medicin
agenc
unit
state
food
drug
administr
clinic
trial
new
vaccin
cchf
current
conduct
turkey
cchf
viru
viru
respons
widespread
haemorrhag
fever
world
cornerston
treatment
support
therapi
particular
focu
clot
abnorm
need
transfus
blood
product
fresh
frozen
plasma
ion
abnorm
may
appear
although
moment
condit
lack
specif
treatment
ribavirin
drug
may
provid
benefit
even
though
studi
publish
offer
contradictori
result
regard
postexposur
prophylaxi
ribavirin
commonli
use
drug
use
recommend
case
highrisk
exposur
howev
specif
efficaci
data
wellestablish
regimen
respect
dose
durat
prophylaxi
author
declar
conflict
interest
